Concepts, Mechanisms, and New Targets for Chemotherapy

  • F. M. Muggia

Part of the Cancer Treatment and Research book series (CTAR, volume 78)

Table of contents

  1. Front Matter
    Pages i-x
  2. Concepts and Mechanisms

    1. Front Matter
      Pages 1-1
    2. Philip A. Philip, Adrian L. Harris
      Pages 3-27
    3. William J. Slichenmyer, Ross C. Donehower
      Pages 29-43
    4. George A. Fisher, Bert L. Lum, Branimir I. Sikic
      Pages 45-70
    5. Robert B. Diasio, Zhihong Lu, Ruiwen Zhang, Harout S. Shahinian
      Pages 71-93
    6. Carla Van Den Berg, Daniel D. Von Hoff
      Pages 95-114
    7. Colin Paul Spears, Göran Carlsson, Franco M. Muggia, George Jaresko, Bengt G. Gustavsson
      Pages 115-134
  3. Disease Targets

    1. Front Matter
      Pages 135-135
    2. Raymond A. Kempf
      Pages 137-162
    3. Willi Kreis
      Pages 163-184
    4. John P. Crown, David Fennelly
      Pages 209-226
  4. Back Matter
    Pages 227-237

About this book


Concepts, Mechanisms, and New Targets for Chemotherapy describes new interconnections between rationally designed and empirically discovered compounds. One route that has not been travelled previously is that of protein kinase C inhibition. This pathway may be exploited to give potent inhibitors, such as the bryostatins, now in clinical trial. A summary is given of the current status of topoisomerase, focusing on recent clinical advances with camptothecin analogs based on connecting empiricism with concepts of drug selectivity.
Modification of existing therapies based on the pursuit of leads arising from mechanistic studies is also being applied clinically on a wide scale. Greater understanding should follow from the studies of reversal of the multidrug resistant phenotype, on the use of hydroxyurea to reverse resistance mediated by extrachromosomal DNA, and on various aspects of the fluoropyrimidine pathways.
Successful applications of chemotherapy to the treatment of specific diseases include the growing applications of systemic therapy using various skin malignancies. In prostate cancer, estramustine phosphate will likely play an expanding role. Taxanes are restructuring treatment regimens in breast cancer, and high-dose strategies are described with peripheral blood progenitor autografting in the treatment of ovarian and breast cancers.


DNA breast cancer cancer carcinoma chemotherapy clinical trial diseases neoplasm prostate cancer systemic therapy therapy tumor

Editors and affiliations

  • F. M. Muggia
    • 1
  1. 1.University of Southern California Cancer CenterUSA

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 1995
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-5829-9
  • Online ISBN 978-1-4615-2007-8
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site